3-((1H-imidazol-1-yl)methyl)-6-methyl-2-p-tolylimidazo[1,2-a]pyridine → ethyl 1-((2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)-5-methyl-1H-pyrazole-3-carboxylate
反応式
N1(CC2N3C=C(C)C=CC3=NC=2C2C=CC(C)=CC=2)C=CN=C1.Cl.Cl[CH2:26][C:27]1[N:31]2[CH:32]=[CH:33][CH:34]=[CH:35][C:30]2=[N:29][C:28]=1[C:36]1[CH:41]=[CH:40][C:39]([Cl:42])=[CH:38][CH:37]=1.[CH3:43][C:44]1[CH:48]=[C:47]([C:49]([O:51][CH2:52][CH3:53])=[O:50])[NH:46][N:45]=1>>[Cl:42][C:39]1[CH:40]=[CH:41][C:36]([C:28]2[N:29]=[C:30]3[CH:35]=[CH:34][CH:33]=[CH:32][N:31]3[C:27]=2[CH2:26][N:45]2[C:44]([CH3:43])=[CH:48][C:47]([C:49]([O:51][CH2:52][CH3:53])=[O:50])=[N:46]2)=[CH:37][CH:38]=1参加物
反応物 3
生成物 1
実験手順
The title compound was prepared according to Method A and the experimentals described for compound 1 from 3-(chloromethyl)-2-(4-chlorophenyl)imidazo[1,2-a]pyridine hydrochloride and ethyl 3-methyl-1H-pyrazole-5-carboxylate. The regioisomers were separated by silica gel chromatography. Compound 28: M/e+ 395 for C21H20ClN4O2 (M+H)+; 1H-NMR (400 MHz, CDCl3) δ 8.24 (d, J=6.9 Hz, 1H), 7.82 (d, J=8.4 Hz, 2H), 7.61 (d, J=8.8 Hz, 1H), 7.36 (d, J=8.4 Hz, 2H), 7.17 (td, J=6.6, 1.1 Hz, 1H), 6.78 (td, J=6.6, 1.1 Hz, 1H), 6.50 (s, 1H), 6.01 (s, 2H), 4.30 (q, J=7.3 Hz, 2H), 2.26 (s, 3H), 1.30 (q, J=7.3 Hz, 3H) ppm; Compound 29: M/e+ 395 for C21H20ClN4O2 (M+H)+; 1H-NMR (400 MHz, CDCl3) δ 8.47 (d, J=6.6 Hz, 1H), 7.64 (d, J=8.4 Hz, 2H), 7.63 (m, 1H), 7.48 (d, J=8.4 Hz, 2H), 7.24 (t, J=6.6 Hz, 1H), 6.84 (t, J=6.6 Hz, 1H), 6.44 (s, 1H), 5.84 (s, 2H), 4.36 (q, J=7.3 Hz, 2H), 1.73 (s, 3H), 1.37 (t, J=3H) ppm.
後処理
- customThe regioisomers were separated by silica gel chromatography
出典と根拠
- ORDレコード
- ord-11b2cdb4aea84439a965d614ae80ce92
- 出典データセット
- uspto-grants-2013_07
- 特許番号
- US08497278B2
反応ノート
読み込み中…